Fuli Kangzuo (伏立康唑)伏立康唑

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

伏立康唑是一种在国家药监局注册认定的药品。该药品含有伏立康唑-64b849f6等成分。

该药品关联的活性成分包括:伏立康唑Fuli Kangzuo。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:四川美大康华康药业有限公司Chinese legal name: 四川美大康华康药业有限公司。

您可以探索含有相同成分的其他药品:伏立康唑-64b849f6成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 伏立康唑) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 伏立康唑Fuli Kangzuo.

Manufacturers recorded for this product: 四川美大康华康药业有限公司Chinese legal name: 四川美大康华康药业有限公司.

Explore other medicines containing the same ingredient: 伏立康唑 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 伏立康唑Recorded Chinese name: 伏立康唑
  • 规格Specification: ----

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 四川美大康华康药业有限公司Chinese legal name: 四川美大康华康药业有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H20052299

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H20052299

Manufacturer

Chinese legal name: 四川美大康华康药业有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

English translation unavailable. The original Chinese source label remains available below.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H20052299

生产企业

四川美大康华康药业有限公司(国产)

适应症

控制口腔、咽喉、食管的白色念珠菌病和曲菌性侵入疾病,或用于控制HIV/AIDS者的机会性真菌感染。

用法用量

1.口服:用于控制口腔、咽喉、食管的白色念珠菌病和曲菌性侵入疾病,每次200mg,每天2次。 2.静注:每次3~6mg/kg,每天2次,或先期给予负荷量,维持治疗以口服给药替代。

不良反应

本品相对安全。常见AST、ALT升高,发生率为10%~15%。过敏反应、疼痛、瘙痒、红肿、皮疹,发生率为1%~5%。短暂的与剂量相关的视觉障碍、视力模糊,发生率为8%~10%。

禁忌

对本品过敏者禁用。

注意事项

1.妊娠及哺乳妇女慎用。
2.肝功能不全者慎用。
3.对视觉功能不全者需要监护。

贮藏

密封,置阴凉处。

规格

----

证据Evidence

  • 批准文号: 国药准字H20052299
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.